RxDoctor Payments Data

Abhay Bilolikar, MD

Cardiovascular Disease · Royal Oak, MINPI 1083731392

Payments from drug & device makers

$3,192in general payments, 2019–2025

Across 44 payments — averaging $72.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Boston Scientific$549
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$239
  • Siemens Medical Solutions USA, Inc.$168
  • Heartflow, Inc.$110
  • Stryker$84
  • plus $209 from 6 others

What the payments were for

  • Food & beverage$1,357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,192 in reported general payments places this provider in the 50th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$89,425
Medicare patients
800
Services billed
1,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$236,276
XareltoRivaroxaban82$112,915
Repatha SureclickEvolocumab108$66,300
JardianceEmpagliflozin39$52,443
EntrestoSacubitril/Valsartan56$45,625
Praluent PenAlirocumab48$24,848
MultaqDronedarone Hcl14$14,989
Carvedilol ErCarvedilol Phosphate25$12,467
Rosuvastatin Calcium203$4,226
Ranolazine ErRanolazine15$3,699
Metoprolol Succinate146$2,646
Carvedilol175$2,251
Losartan Potassium135$2,147
Atorvastatin Calcium174$2,068
Ezetimibe76$1,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$236,276185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →